糖尿病与终末期肾病在慢性肢体威胁性缺血开放血运重建中的交互作用
基于血管质量倡议数据库2003年至2020年1058例终末期肾病合并慢性肢体威胁性缺血行腹股沟下旁路术的患者,比较糖尿病与非糖尿病患者的结局。糖尿病组围手术期主要不良肢体事件风险更高(OR 1.34),1年主要不良肢体事件率更高(43% vs 32%),但1年原发通畅率和免截肢生存率无显著差异。终末期肾病的风险似乎超过糖尿病,无叠加效应。
要点
- 终末期肾病患者行腹股沟下旁路术时,糖尿病增加围手术期和1年主要不良肢体事件风险。
- 糖尿病未显著影响1年原发通畅率和免截肢生存率。
- 终末期肾病的风险可能超过糖尿病,两者无叠加效应。
核心结论
- 糖尿病和终末期肾病各自独立预测慢性肢体威胁性缺血患者腹股沟下旁路术后早期和晚期主要不良肢体事件。
- 在终末期肾病患者中,糖尿病可能增加围手术期不良事件,但不影响1年原发通畅率和免截肢生存率。
- 终末期肾病的风险特征似乎超过糖尿病,无叠加效应。
研究设计与样本
- 回顾性队列研究,使用血管质量倡议数据库2003年1月至2020年3月的数据。
- 纳入所有因慢性肢体威胁性缺血行初次腹股沟下旁路术的终末期肾病患者,共1058例(66%男性),其中糖尿病组726例(69%),非糖尿病组332例。
- 比较两组围手术期和1年全因死亡、再干预、免截肢生存率和主要不良肢体事件。
主要发现
- 糖尿病组更年轻(中位年龄65岁 vs 68岁,P=0.002),肥胖比例更高(34% vs 19%,P<0.001),当前吸烟者更多(26% vs 19%,P=0.013)。
- 糖尿病组组织缺损更常见(76% vs 66%,P<0.001),更常行胫动脉远端旁路吻合(57% vs 45%,P<0.001)。
- 糖尿病独立关联更高的围手术期主要不良肢体事件(OR 1.34;95%CI 1.06-1.68;P=0.013),但未增加原发通畅率丧失以及截肢或死亡复合结局的风险。
- 平均随访11.4±5.5个月,糖尿病组1年主要不良肢体事件率显著更高(43% vs 32%;P=0.001),但1年原发通畅率和免截肢生存率无显著差异。
- 调整混杂因素后,糖尿病组主要不良肢体事件风险显著增加(HR 1.34;95%CI 1.06-1.68;P=0.013),但免截肢生存率(HR 1.16;95%CI 0.91-1.47;P=0.238)和原发通畅率丧失(HR 1.04;95%CI 0.79-1.37;P=0.767)风险未显著增加。
临床怎么用
- 对终末期肾病合并糖尿病的慢性肢体威胁性缺血患者行腹股沟下旁路术时,应关注较高的围手术期和1年主要不良肢体事件风险。
- 糖尿病不显著影响1年原发通畅率和免截肢生存率,终末期肾病的风险可能更为突出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischemia (CLTI) in patients with end-stage renal disease (ESRD) confers a significant survival disadvantage and is associated with a high major amputation rate. Moreover, diabetes mellitus (DM) is an independent risk factor for developing CLTI. However, the interplay between end-stage renal disease (ESRD) and DM on outcomes after peripheral revascularization for CLTI is not well established. Our goal was to assess the effect of DM on outcomes after an infrainguinal bypass for CLTI in patients with ESRD. METHODS: Using the Vascular Quality Initiative dataset from January 2003 to March 2020, records for all primary infrainguinal bypasses for CLTI in patients with ESRD were included for analysis. One-year and perioperative outcomes of all-cause mortality, reintervention, amputation-free survival (AFS), and major adverse limb event (MALE) were compared for patients with DM versus those without DM. RESULTS: Of a total of 1,058 patients (66% male) with ESRD, 726 (69%) patients had DM, and 332 patients did not have DM. The DM group was younger (median age, 65 years vs. 68 years; P = 0.002), with higher proportions of obesity (body-mass index>30 kg/m2; 34% vs. 19%; P < 0.001) and current smokers (26% vs. 19%; P = 0.013). The DM group presented more frequently with tissue loss (76% vs. 66%; P < 0.001). A distal bypass anastomosis to tibial vessels was more frequently performed in the DM group compared to the non-DM group (57% vs. 45%; P < 0.001). DM was independently associated with higher perioperative MALE (OR 1.34; 95% CI, 1.06-1.68; P = 0.013), without increased risks of loss of primary patency and composite outcomes of amputation or death. On the mean follow-up of 11.4 ± 5.5 months, DM patients had a significantly higher rate of one-year MALEs (43% vs. 32%; P = 0.001). However, the one-year primary patency and AFS did not differ significantly. After adjusting for confounders, the risk-adjusted hazards for MALE (HR 1.34; 95% CI, 1.06-1.68; P = 0.013) were significantly increased in patients with DM. However, DM was not associated with increased risk of AFS (HR 1.16; 95% CI, 0.91-1.47; P = 0.238), or loss of primary patency (HR 1.04; 95% CI, 0.79-1.37; P = 0.767). CONCLUSIONS: DM and ESRD each independently predict early and late major adverse limb events after an infrainguinal bypass in patients presenting with CLTI. However, in the presence of ESRD, DM may increase perioperative adverse events but does not influence primary patency and AFS at one year. The risk profile associated with ESRD appears to supersede that of DM, with no additive effect.
引用
- Chang H, Rockman CB, Jacobowitz GR, et al. Interplay of Diabetes Mellitus and End-Stage Renal Disease in Open Revascularization for Chronic Limb-Threatening Ischemia. Ann Vasc Surg. 2020. PMID: 33227468. doi:10.1016/j.avsg.2020.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。